Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- An Overview of Drug Discovery and Development
-
1. Rules and filters and their impact on success in chemical biology and drug discovery
- Dr. Christopher Lipinski
-
2. Where did drugs come from?
- Dr. David Swinney
- Target Selection in Early Stage Drug Discovery
-
3. G-Protein coupled receptors in drug discovery
- Dr. Mark Wigglesworth
-
4. Enzymology in drug discovery 1
- Prof. Robert Copeland
-
5. Enzymology in drug discovery 2
- Prof. Robert Copeland
-
6. Inhibiting protein-protein interactions 1
- Dr. Adrian Whitty
-
7. Inhibiting protein-protein interactions 2
- Dr. Adrian Whitty
- Key Drug Discovery Challenges in Major Therapeutic Areas
-
8. Current trends in antiviral drug development
- Prof. Dr. Erik De Clercq
-
9. The challenge of developing drugs for neglected parasitic diseases
- Prof. James Mckerrow
-
10. Is there a role for academia in drug discovery
- Dr. Adrian J. Ivinson
-
11. Key drug discovery challenges in cardiovascular medicine
- Dr. Dan Swerdlow
- Dr. Michael V. Holmes
- Methods of Hit Identification
-
12. Fragment-based lead discovery
- Dr. Daniel A. Erlanson
- Medicinal Chemistry and SAR
-
13. Hit to lead
- Dr. Michael Rafferty
-
14. Prodrug strategies to overcome problems in drug therapy
- Prof. Jarkko Rautio
-
15. Deep ocean microorganisms yield mechanistically-novel anticancer agents
- Prof. William Fenical
- From Lead to Drug
-
16. Biomarkers in drug development: potential use and challenges
- Dr. Abdel-Bassett Halim
- Case Studies in Drug Discovery
-
17. Current concepts for the management of patients with osteoporosis
- Dr. Michael Lewiecki
-
19. Teixobactin kills pathogens without detectable resistance
- Prof. Kim Lewis
-
20. Discovery of schizophrenia drug targets from DISC1 mechanisms
- Prof. Atsushi Kamiya
- Archived Lectures *These may not cover the latest advances in the field
-
21. CNS-drug design
- Prof. Quentin Smith
-
22. Imatinib as a paradigm of targeted cancer therapies
- Prof. Brian Druker
-
23. New and emerging treatments for osteoporosis
- Dr. Michael Lewiecki
-
24. Prodrugs and drug delivery
- Prof. Jarkko Rautio
Printable Handouts
Navigable Slide Index
- Introduction
- Goals
- Key references and disclaimer
- Reversible modes of enzyme inhibition
- Enzyme-inhibitor binding equilibria
- Effects of inhibitors on catalysis steps
- Inhibition modalities
- Competitive enzyme inhibitors in clinical use
- Lovastatin inhibition of HMG-CoA reductase
- Captopril and enalaprilate inhibition of ACE
- Competitive inhibitors of HIV protease
- Noncompetitive enzyme inhibitors in clinical use
- NNRTI inhibition of HIV reverse transcriptase
- Uncompetitive enzyme inhibitors in clinical use
- Methotrexate inhibition of DHFR
- Dissociation constants: DHFR-ligand complexes
- DHFR interactions with methotrexate and DHF
- Inhibition of 5-alpha reductase (1)
- Inhibition of 5-alpha reductase (2)
- Dead end inhibitor modality
- Advantages of reversible inhibition modalities
- Common non-classical modes of inhibition
- Enzyme assays for inhibitor discovery
- Assay criteria for screening
- Factors that can affect enzyme assays
- Laboratory measures of enzyme reactions
- Balanced assay conditions
- Balanced conditions and physiological context
- Screening for inhibitors of DHFR (1)
- Screening for inhibitors of DHFR (2)
- Measure of signal robustness
- Hit declaration criteria
- False positives
- Promiscuous inhibitors
- HTS compound follow-up
- Enzyme inhibitors during lead optimization
- Compound evaluation flowchart
- Concentration-response plots
- Compound IC50 values
- Effect of substrate on IC50
- Cheng-Prusoff relationships
- Hill coefficient
- Why report Hill coefficients?
- Biphasic binding
- Non-ideal 4-parameter fits
- Non-ideal 2-parameter fits
- Testing for inhibitor reversibility
- Defining inhibitor modality and Ki
- Selectivity in terms of relative Ki values
- The value of knowing inhibitor modality
- Suggestions for data reporting
- Cellular effects and target enzyme inhibition
- Cellular effects and target engagement
- Enzyme-cellular correlation plot
- Summary
Topics Covered
- Enzymes as targets for drug discovery
- Protein-ligand binding equilibria
- Enzyme reaction mechanisms
- Structure and function of enzyme active sites
- Measuring enzyme velocity in the laboratory
- Reversible modes of enzyme inhibition
- Enzyme inhibition as a mechanism of pharmacological intervention in disease
- Clinical value of different inhibition modalities
- Non-classical inhibition
- Enzyme assays and screening criteria
- Lead optimization
- Summary: basic information to look for
Talk Citation
Copeland, R. (2013, September 23). Enzymology in drug discovery 2 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 27, 2024, from https://doi.org/10.69645/BVJF6644.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Robert Copeland has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Enzymology in drug discovery 2
Published on September 23, 2013
66 min
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:12
Reversible modes of enzyme inhibition.
In this lecture, we will explore how different types of
reversible inhibitors can interact with enzymes
to form the basis of pharmacological intervention.
0:28
This slide summarizes, as a thermodynamic cycle,
the different ways that a modulatory compound can interact with an enzyme.
If a compound binds to the free enzyme in a way that competes with the substrate,
that compound is referred to as a competitive inhibitor.
The Kd for that compound is given the special symbol Ki.
On the other hand, if the compound binds exclusively to the ES binary complex,
that is referred to as an uncompetitive inhibitor.
The Kd for that type of inhibitor is given the special symbol αKI.
It's also possible for a compound to bind to
both the free enzyme and to the ES binary complex.
Such a compound is referred to as non competitive.
To the describe the affinity of that compound,
we have to describe two Kd values.
Ki for the affinity of the EI binary complex,
and αKi for the ternary ESI complex.
Some researchers use the term non-competitive exclusively for
situations where the affinity of the inhibitor
for the free enzyme and for the ES complex is identical.
In other words, an α value of one.
They instead use the term mixed inhibition for situations where α is other than one.
For convenience, we will use the term non-competitive inhibitor to refer to
all situations where the compound has
affinity for both the free enzyme and the ES complex,
regardless of what the value of α is.
You can also see on this slide, that when the ESI ternary complex is formed,
it is possible that the reaction will go on to form product with a K_cat value
different from that in the absence of inhibitor.
The K_cat is modulated in this situation by the constant β.
Now in most situations of inhibition,
β is equal to zero.
That type of inhibition is referred to as dead end inhibition.
That is the most useful type of inhibition to go on to
pharmacological intervention to form the basis of a drug molecule.
If β is less than one but not zero,
that situation is referred to as partial inhibition.
There are examples of partial inhibitors that are used as drugs,
but it's a rare situation.
The other possibility is if β is greater than one,
in fact, the binding of the compound enhances the catalytic activity of the enzyme.
In that case, the molecule would be referred to as
an activator rather than an inhibitor.
There are examples of metabolites in biology that act as enzymes activators.
But we will not speak about those further in these lectures
because very rarely is an activator of an enzyme used as a drug molecule.